The global uveitis treatment market size is expected to reach USD 765.31 million by 2026. It is projected to register a CAGR of 5.8% during the forecast period. Rising prevalence of the condition is anticipated to drive the growth. For instance, according to The Ocular Immunology and Uveitis Foundation, around 43,000 new eye inflammation cases are being diagnosed each year in U.S.
Access Sample Report of this report @ https://www.radiantinsights.com/research/uveitis-treatment-market/request-sample
Eye inflammation is also very prevalent among children. However, majority of the affected population ranges from 20 to 50 years of age. Growing geriatric population is also an important factor driving the growth of the market. Rise in number of R&D activities aiming at new drug development is another attribute increasing the demand for these treatments.
For instance, ADX-102 Ophthalmic Solution, by Aldeyra Therapeutics, Inc. is in Phase 2 clinical trial for the treatment of noninfectious anterior uveitis. The National Eye Institute is also engaged in conducting and supporting various research studies in this field. Increasing prevalence of infectious diseases is another contributing factor to the market growth. Infectious uveitis surrounds a significant array of potential pathogens, which is likely to pose immense threat to the people affected.
Further key findings from the study suggest:
- Corticosteroids led the market in 2018 owing to its wide application for treating noninfectious uveitis as well as availability of varied corticosteroids drugs
- Monoclonal antibodies are expected to exhibit lucrative CAGR over the forecast period due to rising development of novel biologic drugs
- Anterior held the largest market share in 2018 owing to growing prevalence and tendency of recurrence of anterior uveitis
- Posterior is anticipated to showcase lucrative growth over the forecast period owing to rise in the number of R&D and clinical trials undergoing for the treatment posterior uveitis
- Noninfectious segment held significant revenue share in 2018 owing to the wide array of treatment methods coupled with rising cases of the condition
- Infectious segment is gaining traction in the uveitis treatment market owing to rising prevalence of infectious diseases
- North America held the largest revenue share in 2018 owing to increasing prevalence of noninfectious uveitis as well as rising healthcare expenditure in this region
- Asia Pacific is anticipated to exhibit lucrative CAGR over the forecast period due to the rising number of infectious diseases in the developing countries
- Few major companies are Allergan, Inc.; Valeant Pharmaceutical International, Inc.; Eyegate Pharmaceuticals, Inc.; AbbVie Inc.; Regeneron Pharmaceuticals, Inc; and Santen Pharmaceutical Co., Ltd
Browse Full Report With TOC @ https://www.radiantinsights.com/research/uveitis-treatment-market
Continued…
About Radiant Insights
Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.
Media Contact:
Michelle Thoras
201 Spear Street 1100,
Suite 3036, San Francisco,
CA 94105, United States
Tel: 1-415-349-0054
Toll Free: 1-888-928-9744
Mail: [email protected]
The global molecular diagnostics market size is expected to reach USD 16.16 Billion by 2028 and register a CAGR of 8.2%, according to the latest report by Reports and Data.
Increasing investments in research and development activities, growing awareness about faster diagnostic techniques, and increasing adoption of self-testing kits are fueling the revenue growth of the global market.
This is expected to hamper global market growth in the coming years.
In addition, lack of skilled professionals to operate these instruments is expected to further restrain market growth during the forecast period.
Get a sample of the report @ https://reportsanddata.com/sample-enquiry-form/945The report provides an in-depth analysis of the key developments and innovations of the market such as research and development advancements, product launches, mergers & acquisitions, joint ventures, partnerships, government deals, and collaborations.
The report offers a comprehensive assessment of key players in the market along with their global position, financial standing, business expansion plans, production and manufacturing capacity, and strategic alliances.Key players in the market include Abbott, Roche Diagnostics, QIAGEN, Danaher, Hologic, Becton, Siemens Healthcare GmbH, Bio-Rad Laboratories, Dickinson and Co., CepheidFurthermore, the report segments Molecular Diagnostics market on the basis of key product types and applications and provides details about the revenue growth, revenue CAGR, and revenue share each segment is expected to register over the forecast period.Product and Service Outlook (Revenue, USD Billion, 2018 - 2028)Reagents and KitsInstrumentsTabletop InstrumentsPortable & PoC Instruments Services and SoftwareTechnology Outlook (Revenue, USD Billion, 2018 - 2028)Polymerase Chain Reaction (PCR) Isothermal Nucleic Acid Amplification Technology (INAAT) DNA Sequencing & Next-Generation Sequencing (NGS) In Situ Hybridization DNA Microarray Other TechnologiesApplication Outlook (Revenue, USD Billion, 2018 - 2028)Infectious DiseasesHepatitisHIVCT/NGHAISHPVTuberculosisInfluenzaOther Infectious DiseasesOncology Testing Breast CancerColorectal CancerLung CancerProstate CancerOther CancersGenetic TestsOthersEnd-Use Outlook (Revenue, USD Billion, 2018 - 2028)Hospital and ClinicsDiagnostic LaboratoriesOthersFor a better understanding of the global Molecular Diagnostics market dynamics, a regional analysis of the market across key geographical areas is offered in the report.
The global infectious disease diagnostics market was valued at USD 13.93 Billion in 2016 and projected to reach USD 19.35 Billion in 2022, at a CAGR of 5.6%.
The base year considered for the study is 2016, and the forecast for the market size is provided for the period between 2017 and 2022.
Growth in this market is primarily driven by the increasing global prevalence of infectious diseases, shift in focus from centralized laboratories to decentralized point-of-care testing, and growth in funding for research on infectious disease diagnosticsDownload PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=116764589Global Market Segmentation:The market is broadly segmented into assays, kits, & reagents; instruments; and services & software based on product & service.
The assays, kits, & reagents segment accounted for the largest share of the global market and is expected to register the highest CAGR during the forecast period.
The increasing number of infectious disease diagnostic tests carried out; easy accessibility to a wide range of reagents; and the growing need for reliable, specific, and faster detection of infectious diseases in the early stages are the key factors driving the IDD assays, kits, & reagents market.Based on the disease type, the market is segmented into hepatitis, HIV, HAIs, CT/NG, HPV, TB, Influenza, and other diseases.
The hepatitis diagnostics segment accounted for the largest share of the global market in 2017.
